1. Home
  2. SNGX vs GRNQ Comparison

SNGX vs GRNQ Comparison

Compare SNGX & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • GRNQ
  • Stock Information
  • Founded
  • SNGX 1987
  • GRNQ 2013
  • Country
  • SNGX United States
  • GRNQ Malaysia
  • Employees
  • SNGX N/A
  • GRNQ N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • SNGX Health Care
  • GRNQ Technology
  • Exchange
  • SNGX Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • SNGX 6.1M
  • GRNQ 7.0M
  • IPO Year
  • SNGX 1987
  • GRNQ 2018
  • Fundamental
  • Price
  • SNGX $2.21
  • GRNQ $0.95
  • Analyst Decision
  • SNGX
  • GRNQ
  • Analyst Count
  • SNGX 0
  • GRNQ 0
  • Target Price
  • SNGX N/A
  • GRNQ N/A
  • AVG Volume (30 Days)
  • SNGX 29.1K
  • GRNQ 15.2K
  • Earning Date
  • SNGX 05-09-2025
  • GRNQ 05-12-2025
  • Dividend Yield
  • SNGX N/A
  • GRNQ N/A
  • EPS Growth
  • SNGX N/A
  • GRNQ N/A
  • EPS
  • SNGX N/A
  • GRNQ N/A
  • Revenue
  • SNGX $119,371.00
  • GRNQ $2,727,344.00
  • Revenue This Year
  • SNGX N/A
  • GRNQ N/A
  • Revenue Next Year
  • SNGX N/A
  • GRNQ N/A
  • P/E Ratio
  • SNGX N/A
  • GRNQ N/A
  • Revenue Growth
  • SNGX N/A
  • GRNQ N/A
  • 52 Week Low
  • SNGX $1.83
  • GRNQ $0.80
  • 52 Week High
  • SNGX $14.88
  • GRNQ $2.24
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 42.26
  • GRNQ 51.93
  • Support Level
  • SNGX $2.25
  • GRNQ $0.88
  • Resistance Level
  • SNGX $2.28
  • GRNQ $0.97
  • Average True Range (ATR)
  • SNGX 0.11
  • GRNQ 0.05
  • MACD
  • SNGX -0.01
  • GRNQ 0.01
  • Stochastic Oscillator
  • SNGX 35.48
  • GRNQ 58.33

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

Share on Social Networks: